Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0PB0D
|
||||
| Former ID |
DIB000585
|
||||
| Drug Name |
SRX-251
|
||||
| Synonyms |
AVN-246; SRX-108; SRX-31; SRX-74; Vasopressin V1a antagonist (Raynauds disease/dysmenorrhea), Azevan Pharmaceuticals; Vasopressin V1a antagonist (psychiatric disorders/dysmenorrhea), Azevan
|
||||
| Indication | Dysmenorrhea [ICD9: 625.3; ICD10:N94.4-N94.6] | Phase 1 | [1] | ||
| Company |
Azevan Pharmaceuticals Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Canonical SMILES |
[C@@H]1(COC(=O)N1[C@@H]1C(=O)N([C@@H](C(=O)N(C)Cc2cc(C(<br />F)(F)F)ccc2)CC(=O)N2CCC(CC2)N2CCCCC2)[C@@H]1/C=C/c1cccc<br />c1)c1ccccc1
|
||||
| Target and Pathway | |||||
| Target(s) | Vasopressin V1a receptor | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Vascular smooth muscle contraction | |||||
| Reactome | Vasopressin-like receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Peptide GPCRs | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800025117) | ||||
| REF 2 | Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior. Pharmacol Biochem Behav. 2006 Feb;83(2):169-74. Epub 2006 Feb 28. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.